The Lu-177-PSMA
The Lu-177-PSMA based medicine is injected into the body of the cancer patient. It then binds to the PSMA receptors on metastasised prostate cancer cells. Lu-177 emits damaging radiation, and since the Lu-177 is PSMA-bound to the tumour, the radiation damages the cancer cells, sparing the surrounding healthy tissue.
